



## ***In-vitro* and *In-vivo* Relationship of Gabapentin from Floating and Immediate Release Tablets**

**E. E. Zien El-Deen<sup>1,2\*</sup> and H. A. Yassin<sup>2</sup>**

<sup>1</sup>Department of Pharmaceutical Technology, Faculty of Pharmacy, Tanta University, Tanta, Egypt.

<sup>2</sup>Department of Pharmaceutics, Faculty of Pharmacy, Egyptian Russian University, Cairo, Egypt.

### **Authors' contributions**

This work was carried out in collaboration both authors. Author EEZED designed the study, wrote the protocol and wrote the first draft of the manuscript. Author HAY managed the experimental work as well as analyses of the study and also the literature searches. Both authors read and approved the final manuscript.

### **Article Information**

DOI: 10.9734/JAMMR/2019/V30i630200

#### Editor(s):

(1) Prof. Dr. Emin Umit Bagriacik, Director, Department of Immunology, Immunology Research Center, Faculty of Medicine, Gazi University, Besevler, 06560 Ankara, Turkey.

#### Reviewers:

(1) Syed Umer Jan, University of Balochistan, Pakistan.

(2) Shaikh Amir A, Savitribai Phule Pune University, India.

(3) Haroon Rahim, Sarhad University of Science and Information Technology Peshawar, Pakistan.

Complete Peer review History: <http://www.sdiarticle3.com/review-history/47532>

**Original Research Article**

**Received 09 December 2018**

**Accepted 24 February 2019**

**Published 20 August 2019**

### **ABSTRACT**

Gabapentin is effective against post-traumatic spinal injury-induced neuropathic pain. It requires high dosage and frequency in the management of neuropathic pain. The present research work was an attempt to formulate and evaluate gabapentin gastro-retentive tablets to prolong gastric residence and increase drug absorption and further increase bioavailability. The floating tablets of gabapentin were prepared in two doses (300 and 600 mg) by using two polymers (hydroxyl propyl methyl cellulose and hydroxyl propyl cellulose). Immediate release tablets of gabapentin containing the same doses were prepared and used as reference formulations. The physicochemical characteristics of the prepared tablets were determined (drug content, weight variation, friability, hardness, thickness and diameter). Drug release from the prepared tablets was followed and found that by increasing drug concentration in the tablets release rate increases. Floating tablets showed prolonged drug release (over 96%) to more than 15 hrs. Immediate release tablets showed over 97% drug release within 48 min. *In-vivo* results showed that plasma exposure to gabapentin in animals receiving the drug does not dose

\*Corresponding author: E-mail: [dr.esmat.zein@gmail.com](mailto:dr.esmat.zein@gmail.com);

proportional and therefore may not reach therapeutically useful levels.  $AUC_{0-24}$  and  $C_{max}$  in case of 300 mg tablets are more than those in case of 600 mg tablets. The *in-vivo* release of gabapentin does not correlate with the *in-vitro* release of the drug.

**Keywords:** Gabapentin; floating tablets; sustained release tablets; pharmacokinetics.

## 1. INTRODUCTION

For a large number of drugs, transport across the intestinal epithelium in each segment of GIT is not uniform and often limited to a particular segment (window) only [1]. The oral controlled release delivery becomes more difficult due to the inability to restrain and localize the drug delivery system within the desired region of the GIT. The concept of regulatory drug delivery in the human body has been existence for many years because of major benefits such as improved patient compliance and decreased side effects.

Conventional oral dosage forms often produce fluctuations of drug plasma level that either exceeds safe therapeutic levels quickly or fall below the minimum effective level [2].

Numerous oral controlled release drug delivery systems have been developed to prolong drug release. An important prerequisite for successful performance for an oral controlled release drug delivery system is that the drug should have good absorption throughout the whole GIT in order to ensure continuous absorption of released drug [3].

Gabapentin [1- (aminomethyl) cyclohexane acetic acid] is a structural analogue of  $\gamma$ - amino-butyric acid (GABA) with an incorporated cyclohexyl ring Fig 1.

Gabapentin is a white to off-white crystalline solid and currently marketed as an adjunctive therapy for partial seizures in adults with epilepsy and for the management of postherpetic neuralgia [4]. The drug is used in the amyotrophic lateral sclerosis, painful neuropathic, hot flashes (cancer and/or postmenopausal-related), fibromyalgia, neuralgia, neuropathy, chronic pain, prevention of migraine, with minimal side effect profile when compared with other drugs [5,6].

The medications traditionally used for neuropathic pain include opioid analgesics, non-steroidal anti-inflammatory drugs and tricyclic antidepressants. The use of these antidepressants is limited by unwanted side effects and risk of cardiovascular mortality [7- 9].

For treating the peripheral and neuropathic pain caused by traumatic spinal injuries, gabapentin is used up to 3.6 g/day in tablet, capsule and oral solution [10,11].

Gabapentin is freely soluble in water (4491 mg/l at 25°C), basic and acidic aqueous solutions with dissociation constants  $pK_a$  of 3.68 and 10.7, respectively. The absolute bioavailability of approximately 50% makes gabapentin a good candidate for improvement of its oral bioavailability [12]. Due to the short half-life of gabapentin (5-7 h) frequent dosing (at least three times daily) is required for maintaining the desired drug level for the whole day. But this leads to significant fluctuations in the plasma concentration of gabapentin [13,14].

Gabapentin is associated with the absorption window phenomenon because it is absorbed through a large neutral amino acid transporter (with limited transport capacity) located in the upper small intestine [15,16].

Prolonged stable exposure to gabapentin may provide other clinical benefits; including greater efficacy, prolonged duration of action as well as a reduced incidence of adverse effects related to peak drug levels. However, it has been difficult to achieve these benefits with a sustained release formulation of gabapentin, primarily due to the lack of significant absorption in the large intestine [17,18].

Due to limited capacity nature of transporter, the higher doses of gabapentin cannot give the higher plasma levels therefore to overcome the above limitations; the floating drug delivery systems (FDDS) of gabapentin have been investigated to increase the gastric residence and hence, the increased drug delivery in its absorption window.

In this study, floating tablets containing gabapentin 300mg (F1) and 600 mg (F2) were prepared using hydroxyl propyl methyl cellulose (HPMC) as well as hydroxyl propyl cellulose (HPC) in order to improve the drug release with prolonged drug delivery. The prepared tablets were evaluated for *in-vitro* and *in-vivo* activity.




Fig. 1. Chemical structure of gabapentin and  $\gamma$ - amino-butyric acid

## 2. MATERIALS AND METHODS

Gabapentin was obtained from Sigma- Aldrich, (St. Louis, Mo, USA), HPMC k15 and HPC were obtained from Shinyo Puse Chemicals Co., Japan, Magnesium stearate and Aerosil were obtained from S D Fine Chem. Mumbai. Deionized water was purified using Milli-Q system (Millipore, Modified. MA, USA). Potassium dihydrogen phosphate and sodium hydroxide were of analytical grade. Other excipients were of reagent grades.

Preparation of gabapentin floating tablets:

Gabapentin floating tablets were prepared adopting wet granulation technique. Table 1 shows the composition of the proposed gabapentin floating tablets (F1 and F2). Table 2 shows the composition of gabapentin immediate release tablets.

### 2.1 Preparation of Gabapentin Immediate Release Tablets

Tablet 2 shows the composition of the proposed immediate release gabapentin tablets (F3 and F4).

The utilized wet granulation technique using a water-ethanol mixture (1:1) was as follows: a solution was prepared to contain HPMC (K15), HPC (EF) and aerosil which were added to gabapentin bulk powder to improve its poor compressibility. After kneading, it was sieved to form granules (60 mesh sieve, 0.425 mm diameter) and then dried to 3% moisture content (SHIMADZU Moisture Balance, Moc 120H, T-RI-015). The granules were sieved again and mixed carefully with the required quantity of magnesium stearate and the final blend was mixed thoroughly for 5 min and compressed into tablets of the average weight of 470 and 940 mg. Coating of the prepared tablets was then done by the method adopted by Leon Lashman et al. [19]. The weights of the coated tablets were 482 and 965 mg respectively.

### 2.2 Infrared Spectroscopy (FTIR)

A qualitative IR investigation been performed for pure gabapentin, gabapentin with HPMC (K15) and gabapentin with HPC (EF). Samples of 2-3 mg were ground and mixed with potassium bromide (IR grade), compressed into disks in the compressor unit under vacuum at a pressure of 10 ton/cm<sup>2</sup> and scanned from 4000 cm<sup>-1</sup> to 400 cm<sup>-1</sup> with an empty pellet holder acting as a reference using FTIR analyzer (Perkin Elmer model).

FT-IR studies were carried out to check for any interaction between the drug and the polymer. Chemical integrity of the drug was determined by comparing the IR spectra of the drug and drug coated with the chosen polymer.

### 2.3 X-ray Diffractometry (XRD)

X-ray Diffractometry of gabapentin granules was performed by a diffractometer using model (Joel JDX-8030, Japan) equipped with a graphite crystal monochromator (Cu-K $\alpha$ ) radiations to observe the physical state of drug in the granules.

### 2.4 Drug Content

Ten tablets were powdered in a mortar (either containing 300 mg or 600 mg gabapentin (F1, F2, F3 & F4) respectively). A quantity equivalent to 100 mg of gabapentin was transferred to a 100 ml volumetric flask containing 10 ml of phosphate buffer with pH of 6.8. Flask was shaken for some time and made up the volume to 100 ml with the buffer. Ten ml of primary stock solution were taken into another volumetric flask and made up to volume with buffer. The absorbance was measured spectrophotometrically at 210 nm using the buffer as a blank [19].

**Table 1. Composition of gabapentin floating tablets**

Martial Name	Quantity mg/ tablet	
	F1	F2
<b>Active Ingredient</b>		
• Gabapentin	300	600
<b>Inactive Ingredient</b>		
• Hydroxyl propyl methyl cellulose (K15)	160	320
• Hydroxyl propyl cellulose (EF)	30	60
• Aerosil 200	5	10
• Magnesium stearate	5	10
<b>Coat</b>		
• Hydroxyl propyl methyl cellulose (ES)	8.5	17
• Polyethylene glycol 6000	2	4
• Titanium oxide	1.5	3
• Talc	0.5	1

**Table 2. Composition of gabapentin immediate release tablets**

Martial Name	Quantity mg/ tablet	
	F <sub>3</sub>	F <sub>4</sub>
<b>Active Ingredient</b>		
• Gabapentin	300	600
<b>Inactive Ingredient</b>		
• Maize starch	30	60
• Crospovidone	30	60
• Microcrystalline cellulose (KG-1000)	69	138
• Microcrystalline cellulose (pH 102)	165	330
• Magnesium stearate	6	12
<b>Coat</b>		
• Hydroxyl propyl methyl cellulose (ES)	10.8	21.6
• Polyethylene glycol 6000	3.6	7.2
• Titanium oxide	1.8	3.6
• Talc	1.8	3.6

**Table 3. Quality control tests of the prepared tablets**

Formulation code	Drug content (%)	Weight variation (mg)	Friability (%)	Hardness (kg/cm <sup>2</sup> )	Thickness (mm)	Diameter (mm)
F <sub>1</sub>	100.22 ± 0.13	510 ± 2.3	0.042 ± 0.01	8.60 ± 0.40	8.50 ± 1.2	16.50 ± 1.1
F <sub>2</sub>	99.98 ± 0.26	1003 ± 4.8	0.053 ± 0.03	8.90 ± 0.30	9.20 ± 1.1	20.10 ± 2.1
F <sub>3</sub>	99.79 ± 0.12	620 ± 2.9	0.036 ± 0.01	8.40 ± 0.21	8.20 ± 1.3	15.20 ± 1.2
F <sub>4</sub>	99.28 ± 0.90	1230 ± 6.2	0.048 ± 0.03	9.30 ± 0.33	9.30 ± 1.6	22.10 ± 1.3

### 2.5 Weight Variation

Twenty tablets were randomly selected and weighed individually and together in a single pan balance (capacity 311 g and sensitivity 0.01 g). The average weight was noted and the standard deviation was calculated. The tablet passes the test if not more than two

tablets fall outside the percentage limit and none of the tablets differs by more than double percentage limit [20].

$$\% \text{ Deviation} = (W_{\text{avg}} - W_{\text{initial}}) / W_{\text{avg}} \times 100$$

Where W<sub>avg</sub>: average weight of tablets, W<sub>initial</sub>: individual weight of tablet.

## 2.6 Friability

Roch Friabilator (Agilent Technologies USA) was utilized in order to test the strength of the tablets. Friability is expressed in percentage (%). Ten tablets were initially weighed ( $W_0$ ) and put into the apparatus [21,22]. The Friabilator was operated at 25 rpm for 4 min or run up to 100 revolutions. The tablets were weighed again ( $W$ ).

The % friability was then calculated by:

$$\% \text{ Friability} = \frac{W_0 - W}{W_0} \times 100$$

Where  $W_0$ : initial weight of tablets,  $W$ : final weight of tablets % friability of tablets less than 1% are considered acceptable.

## 2.7 Hardness

Hardness reflects the ability of a tablet to withstand mechanical shocks while handling. It is tested by utilizing Monsanto hardness tester (Agilent Technologies, USA). The value is expressed in  $\text{kg.cm}^{-2}$ . Ten tablets were randomly chosen and the hardness of the tablets was determined [23].

## 2.8 Thickness and Diameter

Physical dimensions of the tablet such as thickness and diameter are essential for consumer acceptance and tablet uniformity. Thickness and diameter of the tablets were measured using Vernier Callipers. It is expressed in mm. Five tablets were used and the average values were calculated [24]. Limits of variation must not exceed  $\pm 5\%$  of the standard.

## 2.9 In-Vitro Drug Release Study

The drug release profiles from the tablets were studied using USP dissolution test apparatus employing paddle type (Type II, Paddle type, Copley, England). The rotation of paddle was fixed at 50 rpm and the temperature of  $37 \pm 0.5^\circ\text{C}$  was maintained throughout the experiment. The dissolution medium was 900 ml phosphate buffer solution (pH 6.8). Samples of 5 ml were withdrawn at predetermined time intervals and were replaced with the same volume of fresh dissolution medium at the same temperature. Aliquots were removed, filtered through 0.45 mm

membrane filter and assayed for gabapentin utilizing double beam UV-Visible spectrophotometer at 210 nm. Each dissolution test was repeated 3 times and the mean values with standard deviations were presented.

## 2.10 In-vivo Study

Healthy male Wistar rats (300-350 g) were used for the study and were obtained from national researches centre (Cairo, Egypt). The rats were kept in standard environmental conditions of light and temperature. The rats were allowed free access to drinking water and standard diet; Rats were used after a resting period of 2 days post procurement. *In-vivo* experimental protocols had the approval of the institutional animal ethics committee (IAEC) (IAEC/PROPOSAL/DB-4/2010). Four rats were used under fasted conditions for 18 hrs. In each experiment (Four experiments, F<sub>1</sub>, F<sub>2</sub>, F<sub>3</sub> & F<sub>4</sub>). One tablet corresponding to either 600 mg or 300 mg drug in the sustained release or immediate release formulation was administered orally to the animals with a washout period at least 1 week between two consecutive administrations. Serial blood samples (1.5 ml each) were collected from the ear vein in a tube at predetermined time intervals extending to 36 h. Plasma was immediately obtained by centrifuging blood samples at 3000 rpm for 10 min. All samples were stored frozen at  $-200^\circ\text{C}$  until analysis. Plasma levels of gabapentin were assayed by HPLC.

## 2.11 Analysis of Gabapentin in Rat Plasma

The HPLC system (Zorbax Eclipse XDBC-8, 250× 4.60 mm, 5  $\mu$ , 40°C), mobile phase is composed of acetonitrile, methanol, buffer (3.0) (7:36:57)%. The detector was set at 210 nm with a flow rate of 0.95 ml/min. A portion of the sample (50  $\mu$ l) was injected into the column.

## 2.12 Calculation of Pharmacokinetic Parameters

The pharmacokinetic parameters were calculated through a weight least-squares procedure, with the aid of the non-linear regression programs, SigmaPlot ver. 8.0 (SPSS Inc., Chicago, IL, U.S.A.) and Micromath Scientist® (Micromath®, Saint Louis, MO, U.S.A.). Plasma drug concentrations for 24 h were used to calculate pharmacokinetic parameters because plasma drug

concentrations at 48 h were less than the limit of quantitation.  $AUC_{0-24}$  is the area under the plasma concentration versus time curve, calculated using the trapezoidal rule for the time interval 0 to the last measurable point, 24 h. Elimination half-life,  $t_{1/2}$  was calculated as follows:  $t_{1/2} = 0.693/ke$ . The peak plasma concentration ( $C_{max}$ ) and time to reach the maximum drug plasma concentration ( $T_{max}$ ) were determined from visual inspection of the concentration-time plots.

### 2.13 Statistical Analysis

One way ANOVA test followed by Tukey posttest was used for comparisons between the treatment and control groups. Data were presented as Mean  $\pm$  SD. The P values  $<0.05$  was considered as significance level during this study.

## 3. RESULTS AND DISCUSSION

### 3.1 Infrared Spectral Analysis

Infrared studies (Figs. 2a, 2b, and 2c) revealed that there is no neither appearance of new peaks nor disappearance of existing peaks, which indicated that there is no interaction between the drug and the polymers used.

The IR spectrum of gabapentin exhibit absorption in the usual -NH stretching regions (3500-3300  $cm^{-1}$ ). However, an IR band absorption in the region of 3200-2800  $cm^{-1}$  was observed, which was due to the -NH<sub>3</sub><sup>+</sup>. The broad peak at 3300  $cm^{-1}$  for gabapentin might be attributed to the stretching vibrational modes of hydroxyl groups of water molecules in the gabapentin hydrate. The peaks near at 2123-2200  $cm^{-1}$  corresponded to the distinct side chain and/or CN stretching vibration of all gabapentin. In the region of 1700-1500  $cm^{-1}$ , the IR bands could be assigned as the ionized asymmetric carboxylate and NH<sub>3</sub><sup>+</sup> deformation vibration, respectively. From 1500 to 1350  $cm^{-1}$ , these bands corresponded also to the asymmetric carboxylate band and/or CH<sub>2</sub> deformation band. Below 1350  $cm^{-1}$ , these peaks might be used as a fingerprint of gabapentin.

IR studies show no interaction between drug and excipients. Additional peaks were absorbed in granules which could be due to the presence of polymers and indicated that there was no chemical interaction between gabapentin and other excipients. The spectra showed no incompatibility between the polymers and gabapentin. The spectra of the polymers and the free drug are given in Fig. (2-a, 2-b and 2-c).

### 3.2 X-ray Diffractometry (XRD)

In order to confirm the physical state of the drug in the microspheres, powder X-ray diffraction studies of the drug alone and drug loaded microspheres were carried out (Fig. 3-a, 3-b and 3-c).

X-ray diffractograms of the samples showed that the drug is completely amorphous inside the granules. This may be due to the conditions used to prepare the granules which lead to complete drug amorphization.

Table 3 shows the various post-compression parameters drug content, weight variation, friability, hardness, thickness and diameter.

From Table 3, all post compression parameters (drug content, weight variation, friability hardness, thickness, diameter as well as tablet parameters) are in the required limits.

### 3.3 In-vitro Release Characteristics

The *In-vitro* release profiles of gabapentin from both types of tablets (sustained & immediate release) in the dissolution media (6.8 buffer solution) are presented in Fig. 4.

Gabapentin was quickly released from the immediate release tablets after a short lag time (3.2- 5.6 min), whereas the mean lag time of the sustained release tablets was relatively delayed (12.8- 20.1 min). Within about 30 min, 60- 70 % of the drug was released from the intermediate release tablets in the dissolution media. The film coating did not prevent the immediate release tablets from quickly releasing the drug in the dissolution medium. Dissolution profiles of gabapentin from immediate release tablets indicated that the drug was quickly dissolved after the disintegration of tablets in the dissolution medium. The sustained release tablets become swollen rather than eroding or disintegrating during the experiment, and remained in the dissolution medium until the end of the experiment. The presence of high

concentration of polymer (hydroxyl propyl methyl cellulose K15 and hydroxyl propyl cellulose EF 38%) of the tablet weight was the cause of increasing the swelling index, and retarding drug release from the tablets. Swelling of the sustained release tablets is considered due to the excellent swelling capacity of hydroxyl propyl methyl cellulose as well as its effect on increasing the medium viscosity. Hydroxyl propyl methyl cellulose has a great role in enhancing tablet floating in the stomach, an effect which increases the residence time of the drug in the GIT enhancing the sustained drug effect [25].

Presence of polymer controls the release of the drug. When a hydrophilic polymer is exposed to aqueous media it undergoes rapid hydration and chain relaxation to form a viscous gelatinous layer (gel layer). The rate of diffusion out of the gel layer and the rate of tablet erosion control the overall dissolution rate and delivery of the drug [26]. The overall drug release is affected by the rate of water uptake as well as the diffusion rate of the drug through the swollen gel. High polymer content results in greater amount of gel being formed. The formed gel increases the diffusion path length of the drug. Its viscous nature also affects the diffusion




Fig. 2. IR spectra of gabapentin free drug (a), gabapentin with HPMC (b), gabapentin with HPC(c)

coefficient of the drug. As a result, a reduction in drug release rate is obtained [27,28]. Seok Rhee et al. [29] and Peng-Ju et al. [30] reported that the dissolution rate for sustained release tablets containing gabapentin are unaffected by pH. Gabapentin is amphoteric in nature and has two  $pK_a$ 's, 3.7 and 10.7 due to the carboxylic acid group and the primary amine group respectively. The drug predominantly exists as cation at acidic pH, and an anion at basic pH and has a zwitterion at intermediate values of pH between two  $pK_a$  values.

### 3.4 *In-vivo* Release Study

Plasma drug concentration vs. time profiles after oral administration of gabapentin in the sustained release as well as immediate-release tablets are shown in Fig. 5.

From the obtained results, it is obvious that large doses (600 mg) showed less bioavailability than small doses. *In-vivo* release of gabapentin did not correlate with the *In-vitro*

release of the drug. Gabapentin has a narrow absorption window as seen with metformin [31] and levodopa [32,33]. Metformin was found to have lower bioavailability than conventional immediate-release tablets [34,35]. Gabapentin is mainly absorbed into the upper gastrointestinal tract [17]. The sustained release tablets could not easily pass through the partially constructed sphincter due to the original size of the sustained release tablets and may remain in the stomach for more than 3h especially if containing a gastroretentive agent. These results are coincided with the time to reach the maximum concentration ( $T_{max}$ ) which was obtained from gabapentin sustained-release tablets. Several researchers highlight the formulation and Evaluation of Ketorolac Tromethamine-loaded Albumin microspheres for Potential Intramuscular Administration [35].

Pharmacokinetic parameters of gabapentin after oral administration of immediate as well as sustained release doses to rats under fasted condition are shown in Table 4.




Fig. 3. X-ray diffraction of gabapentin free drug (a), gabapentin with HPMC (b), gabapentin with HPC(c)

Controlled release systems like floating tablets devoid of any adverse effects like dose dumping which is a quit common adverse effect compared to the conventional release dosage form. These systems are




Fig. 4. Release profile of gabapentin a: from sustained-release tablets, b: from immediate release tablets




Fig. 5. Plasma concentration of gabapentin after oral administration of sustained-release tablets (a) and immediate release tablets (b)

**Table 4. Pharmacokinetic parameters of gabapentin after oral administration to rats**

Parameters	Sustained release tablets		Immediate release tablets	
	F <sub>1</sub>	F <sub>2</sub>	F <sub>3</sub>	F <sub>4</sub>
AUC (µg. hr/ml)	497.12±5.23	398.08±2.89	326.65±6.77	298.39±9.56
C <sub>max</sub> (µg/ml)	37.59±1.65	35.31±1.23	43.88±.37	40.09±0.76
T <sub>max</sub> (h)	2.00±0.21	2.50±0.12	1.40±0.74	2.10±0.23
T <sub>1/2</sub> (h)	5.69±0.53	4.17±0.90	4.36±0.44	3.22±0.71

(Mean ± S.E., n = 3)

Although the floating tablets did not disintegrate and had slow drug release characteristics, it showed similar pharmacokinetics parameters to the immediate release tablets, which rapidly disintegrated & showed fast drug release. Thus the *in-vivo* release of gabapentin did not correlate with the *In-vitro* release of the drug.

#### 4. CONCLUSION

It can be concluded that the floating tablets of gabapentin might serve as a proportional alternative of conventional dosage forms. The *in-vivo* release of the gabapentin does not correlate with the *In-vitro* release of the drug. Increasing the concentration of the drug in the tablet was not followed by an increase in the AUC and C<sub>max</sub>.

#### CONSENT

It is not applicable.

#### ETHICAL APPROVAL

As per international standard or university standard written ethical permission has been collected and preserved by the author.

#### COMPETING INTERESTS

Authors have declared that no competing interests exist.

#### REFERENCES

1. Brahmkar DM, Jaiswal SB. A Textbook of biopharmaceutics and pharmacokinetics. A treatise edn. 1, New Delhi. In

Medical Application of Controlled Release. 1984;2:1-34.

2. Vikramaditya Reddy M, Vijayavani Ch. S, Uma Maheshwara Rao V. Formulation and evaluation of gabapentin muco-adhesive gastron retentive tablets. Int. J. of Ph. and Analyt. Res. 2013;2(4):151-163.
3. Kaushik A, Dwivedi A, Praveen K, Abhinav G. Floating drug delivery system a significant tool for stomach specific release of cardiovascular drugs. Int. J. Drug Dev. and Res. 2012;4(4):116-129.
4. Bryans JS, Wustrow DJ. 3-Substituted GABA analogs with central nervous system activity. Med. Res. Rev. 1999;19: 149-177.
5. Backonja MA, Beydoun KR, Edwards SL, Shwartz V, Gabapentin symptomatic treatment of painful neuropathy in patients with diabetes mellitus. A randomized controlled trials. J. Am Med. Assoc. 1998;280:1831-1836.
6. Celik EC, Erthan B, Lakse E. The clinical characteristics of neuropathic pain in patients with spinal cord injury. Spinal Cord. 2012;50:585-589.
7. Siddall PJ, Taylor DA, Cousins MJ. Classification of pain following spinal cord injury. Spinal Cord. 1997;35:69-75.
8. Thuret S, Moon LD, Gage FM. Therapeutic interventions of the spinal cord injury. Nat. Rev. Neurosci. 2006;7:628.
9. Demirel GH, Yilmaz B, Kesiktas N. Pain following spinal cord injury. Spinal Cord. 1998;36:25-28.
10. To TP, Lim TC, Hill ST, Frauman AG, Cooper N, Kirsas SW, Brown DJ. Gabapentin for neuropathic pain following spinal cord injury. Spinal Cord. 2002;40: 282-285.

11. Rowbotham M, Harden N, Stacey B. Gabapentin for the treatment of postherpetic neuralgia: A randomized controlled trial. *J. Am Med. Assoc.* 1998;280(21):1837-182.
12. Meimandi MS, Mobasher M, Reza G, Nargles A. Gabapentin increases the analgesic effect of chronic use of morphine while decreases withdrawal signs. *Int. J. Pharmacol.* 2005;1:161-166.
13. Hagen EM, Rekand T. Management of neuropathic pain associated with spinal cord injury. *Pain Therapy.* 2015;4:51-65.
14. Mellegers MA, Furlan AD, Mailis A. Gabapentin for neuropathic pain: Systemic review of controlled and uncontrolled literature. *Clin. J. Pain.* 2001;17:284-295.
15. Fennerup NB, Johannsen L, Sindrup SH, Bach FW, Jensen TS. Pain and dysesthesia in patients with spinal cord injury: A postal survey. *Spinal Cord.* 2001;39:256-262.
16. Kukkar A, Bail A, Singh, Jaggi AS. Implications and Mechanism of action of gabapentin in neuropathic pain. *Arch. Pharmacol. Res.* 2013;36:237-251.
17. Stevenson CM, Kim J, Fleisher D. Colonic absorption of antiepileptic agents. *Epilepsia.* 1997;38:63-67.
18. Kriel RL, Birnbaum AK, Cloyd JC, Ricker BJ, Jones, Saete C, Caruso KJ. Failure of absorption of gabapentin after rectal administration. *Epilepsia.* 1997;38:1242-1244.
19. Leon Lachmann, Lieberman HA, Kanig JL. The theory and practice of industrial pharmacy. CBS Publishers and Distributer. 2009:297-301.
20. Shaikh A, Pawar YD, Kumbhar ST. Effect of chitosan and sodium alginate on mucoadhesion on drug release of itraconazole tablets. *Int. J. of Res. in Pharm. Biomed. Sci.* 2012;3(1):293-297.
21. Goswami Dhrnba Sanker. Formulation and evaluation of mucoadhesive tablets of famotidine. *J. of Pharm. And Biomed. Sci.* 2011;12(06).
22. Government of India Ministry of Health and Family Welfare. The pharmacopeia of India Delhi, India. Controller of Publication. 1997;1020-1022.
23. Inderbir GA, Karann M, Inderbir S, Sandeep A, Vikas R. Formulation and evaluation of controlled release matrix mucoadhesive tablets of domperidone using saliva plebeian gum. *J. of Adv. Pharm. Tech. and Res.* 2012;2(3):163-169.
24. Stepensky D, Friedman M, Srour W, Raz I, Hoffman A. Preclinical evaluation of pharmacokinetic-pharmacodynamic rationale for oral CR metformin formulation. *J. Control. Release.* 2001;71:107-115.
25. Klausner EA, Lavy E, Stepensky D, Friedman M, Hoffman A. Novel gastroretentive dosage form evaluation of gastroretentivity and its effect on riboflavin absorption in dogs. *Pharmacol Res.* 2002;19:1516-23.
26. Cao Qing-Ri, Choi Yun-Woong, Cui Jing-Hao, Lee Beom Jin. Formulation, release characteristics and bioavailability of novel monolithic hydroxy propyl methyl cellulose matrix tablets containing acetaminophen. *J. Control. Rel.* 2005;108(2-3):351-361.
27. Tiwari Sandip B, Rajabi-Siahboomi A. Modulation of drug release from hydrophilic matrices. *Pharm. Tech. Europe.* 2008;1:1-8.
28. Tiwari Sandip B, Rajabi-Siahboomi A. Extended release oral drug delivery technology, monolithic matrix system. *Drug Deliv. Syst.* 2008;437:217-243.
29. Yun-Seok Rhee, Seok Park, Tae-Won Lee, Chun-Woong Park, Tae-Young Nam Tack-Oon Oh. *In Vitro/in Vivo* relationship of gabapentin from a sustained-release tablet formulation: A pharmacokinetic study in the beagle dog. *Arch. Pharm. Res.* 2008;31(7):911-917.
30. Peng-Ju Ma, Guo-Jun Gao, Hai-Gang Chang, Fa-Zheng Shen Lei, Bao-Zhe Jin. Prolonged and floating drug delivery system of gabapentin for effective management of pain in spinal cord injury. *Int. J. Pharm.* 2016;10:435-439.
31. Fujioka K, Pans M, Joyal, S. Glycemic control in patients with type 2 diabetes mellitus switched from twice-daily immediate-release metformin to a once-daily extended release formulation. *Clin. Ther.* 2003;25:515-529.
32. Klausner EA, Eyal S, Lavy E, Friedman M, Hoffman. A novel levodopa gastroretentive dosage form: *In-Vivo* vvaluation in dogs. *J. Contr. Rel.* 2003a;88:117-26.
33. Klausner EA, Lavy E, Barta M, Cserepes E, Friedman M, Hoffman A. Novel gasrtretentive dosage forms: Evaluation of gastroretentivity and its effect on levodopa absorption in humans. *Pharmacol Res.* 2003b;20:1466-73.

34. Noel M. Kinetic study of normal and sustained dosage forms of metformin in normal subjects. *Res. Clin. Forums.* 1979;1:35-50.
35. Karttunen P, Uusitupa M, Lamminsivu U. The pharmacokinetics of metformin: A comparison of the properties of a rapid-release and a sustained-release Preparation. *Int. J. Clin. Pharmacol. Ther Toxicol.* 1983;21:31-36.
36. Abdelkader H, Abdalla O, Salem H. Formulation of controlled-release baclofen matrix tablets: Influence of some hydrophilic polymers on the release rate and in vitro evaluation. *AAPS. Pharm. Sci. Tech.* 2007;8:156-166.

© 2018 El-Deen and Yassin; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

*Peer-review history:*  
*The peer review history for this paper can be accessed here:*  
<http://www.sdiarticle3.com/review-history/47532>